US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 
• By Sarah Karlin-Smith
  
small green plant sprouting out of crack in concrete.
The FDA has been able to help revive stuck rare disease programs as its thinking and experience with clinical trial designs evolved. (Shutterstock)

More from Clinical Trials

More from Advanced Technologies